Published in
Ferrata Storti Foundation, Haematologica, 12(94), p. 1676-1681
DOI: 10.3324/haematol.2009.011205
Links
- ORCID
- ORCID
- ORCID
- ORCID
- Ferrata Storti Foundation | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [www.researchgate.net] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [europepmc.org] | PDF
Tools
TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia
Journal article published in 2009 by
Michaë la Fontenay,
Stéphane de Botton,
Cindy Racoeur,
Norbert Vey,
Bruno Quesnel,
Eric Solary,
Aspasia Stamatoulas,
William Vainchenker 
,
Groupe Francophone des Myélodysplasies,
Véronique Gelsi-Boyer,
Valérie Jooste,
Marion Ciudad,
Pierre Fenaux,
Bastie Jn,
Olivier Kosmider
and other authors.
,
Groupe Francophone des Myélodysplasies,
Véronique Gelsi-Boyer,
Valérie Jooste,
Marion Ciudad,
Pierre Fenaux,
Bastie Jn,
Olivier Kosmider
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Postprint:
archiving forbidden
Data provided by 
Abstract
Acquired somatic deletions and loss-of-function mutations in one or several codons of the TET2 (Ten-Eleven Translocation-2) gene were recently identified in hematopoietic cells from patients with myeloid neoplasms. This study shows that TET2 mutations are more frequent in chronic myelomonocytic leukemia than in other subgroups of myeloid neoplasms studied so far.